Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
96 results about "Deoxyadenosine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Deoxyadenosine (symbol dA or dAdo) is a deoxyribonucleoside. It is a derivative of the nucleoside adenosine, differing from the latter by the replacement of a hydroxyl group (-OH) by hydrogen (-H) at the 2' position of its ribose sugar moiety. Deoxyadenosine is the DNA nucleoside A, which pairs with deoxythymidine (T) in double-stranded DNA.
Pharmaceutical formulations targeting specific regions of the gastrointesinal tract
Oral formulations of pharmaceuticals are provided with enhanced bioavailability by targeting specific regions of the gastrointestinal tract. Particularly, water soluble and acid-labile drugs such as cytidine analogs (e.g., decitabine) and 2'-deoxyadenosine analogs (e.g., pentostatin) are formulated with pH-sensitive polymers so that these drugs are preferably absorbed in the upper regions of the small intestine, such as the jejunum. In addition, drugs with poor oral bioavailability such as camptothecin compounds (e.g., 9-nitro-camptothecin) can also be formulated using similar strategies in order to significantly improve their oral bioavailability. These formulations can be used to treat a wide variety of diseases or conditions, such hematological disorders, benign tumors, cancer, restenosis, inflammatory diseases, and autoimmune diseases.
Owner:MAYNE PHARMA USA
Topical composition for treatment of skin disorders
InactiveUS20070142317A1Shelf life stableNon toxicBiocideFlow mixersDiseaseAdenosine Deaminase Inhibitor
The present invention provides for a topical composition that includes a topical carrier and an adenosine deaminase inhibitor. Suitable specific adenosine deaminase inhibitors include, e.g., deoxycoformycin (dCF), deoxyadenosine (dAdo), cladrabine (CdA), fludarabine (F-Ara-A), cytrabine (Ara-C), and thioguanine. The present invention also provides for a method to treat lymphocyte mediated skin diseases and to alleviate symptoms associated with such skin diseases. The method includes topically administering the composition to a mammal in need of such treatment. The present invention also provides for kits and syringe systems that include the adenosine deaminase inhibitor.
Owner:QLT USA INC
Method of artificial planting northerly Chinese caterpillar fungus for increasing content of physiologically active substance
InactiveCN1445360AHigh content of physiologically active substancesIncreased content of physiologically active substancesFungiBiotechnologyActive component
A method for artificially culturing north cordyceps to increase the contents of its physiological active components (cordyceptic acid, cordycepin and cordyceptic polyose) includes such steps as washing fresh wild north cordyceps, section, regulating pH of culture medium to 6-7, sterilizing, shaping slant, slant culturing at 20-25 deg.C for 7-10 days, regulating pH of liquid culture medium to 6-7,sterilizing, inoculating, culturing, preparing solid culture medium from rice and sorghum grains, inoculating, and culturing at 25-29 deg.C for 40-60 days.
Owner:SHENYANG INST OF APPLIED ECOLOGY - CHINESE ACAD OF SCI
Method for testing sequence of nucleic acid single molecule
InactiveCN101654712AFast measurementHigh assay qualityMicrobiological testing/measurementRaman scatteringPhosphoric acidWaveguide
The invention relates to a method for testing a sequence of a nucleic acid single molecule in the technical field of biology, which comprises the following steps: respectively detecting Raman spectrumsignals of deoxyadenosine 5'-phosphoric acid, deoxyguanosine 5'-phosphoric acid, deoxycytidine 5'-phosphoric acid, deoxythymidine 5'-phosphoric acid, methyldeoxycytidine 5'-phosphoric acid, adenosine5'-phosphoric acid, vernine 5'-phosphoric acid, cytidine 5'-phosphoric acid and uridine 5'-phosphoric acid and establishing a standard curve; cutting a nucleic acid molecule to be detected by exonclease and detecting the Raman spectrum signal transmitted by a cut product when passing through a zero mode waveguide by the trigger of a laser; converting the Raman spectrum signal obtained in the step2 into concrete ribotide according to the standard curve obtained in the step 1 and obtaining the concrete sequence of the nucleic acid molecule to be detected by combining the cutting direction of the exonclease. The method can directly detect a natural nucleic acid sequence without a mark and has high detecting speed and detecting quality and low detecting cost.
Owner:SHANGHAI JIAO TONG UNIV
Deoxyadenosine in aplication of preparing bypolipidemic
An application of 3'-deoxyadenosine in preparing the medicine for decreasing blood fat, especially the serum triglyceride, is disclosed.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI +1
Method for detecting enteritis pathogenic bacteria
ActiveCN102154450AAvoid damageCause drug resistanceMicrobiological testing/measurementBacteroidesRibosomal DNA
The invention relates to a method for detecting bacteria, in particular to a method for detecting enteritis pathogenic bacteria. The method comprises the following steps of: (1) extracting DNA (Deoxyribonucleic Acid) of one or more bacteria samples; (2) amplifying full length of 16S rDNA (ribosomal DNA) of a sample by using a primer of 16S rDNA of bacteria; (3) breaking an amplified PCR (Polymerase Chain Reaction) product; (4) repairing ends of the broken product from each bacteria sample and connecting deoxyadenosine at the end 3' of the product, and then connecting different PCR-free joints; (5) sequencing a connection product by using a second-generation sequencing technology to obtain a sequence of the connection product; and (6) comparing the sequence with 16S rDNA reference sequences of all existing bacteria to determine types of bacteria existing in each sample.
Owner:深圳华大因源医药科技有限公司
Formulations of phosphoramidate derivatives of nucleoside drugs
InactiveUS20180369266A1Mitigates risk of precipitationDirect contact guaranteeOrganic active ingredientsPharmaceutical delivery mechanismPhosphateDeoxyuridine
This invention relates to pharmaceutical formulations and formulation strategies of protides (phosphoramidate derivatives of nucleosides) and, in particular, protides useful in the treatment of cancer, such as NUC-3373 (5-fluoro-2′-deoxyuridine-5′-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate) and NUC-7738 (3′-deoxyadenosine-5′-O-[phenyl(benzyloxy-L-alaninyl)] phosphate). In particular, the invention relates to formulations that comprise a polar aprotic solvent, for example, dimethyl acetamide (DMA).
Owner:NUCANA PLC
Process for extracting compound cordycepin and its Chinese medicine
InactiveCN1396172AHigh medical valueImprove clinical outcomesOrganic active ingredientsSugar derivativesN-ButanolImpurity
A process for extracting complex cordycepin includes such steps as immersing the powdered cordyceps in water for 8-14 hr, extracting by alcohol or by decocting and alcohol deposition, filtering to obtain liquid medicine, concentrating reflux of alcohol, eluting with ionic column, concentrating, cold storage at 0 deg.C for 24 hr, crystallizing, and recrystallizing with n-butanol. The cordycepin contains 2'-deoxyadensine and 3'-deoxyadenosine compound and has high anticancer action.
Owner:吉林省吉庵堂医药研究所
Serum-free culture medium for mesenchymal stem cells and application thereof
ActiveCN110331130AShort cycleImprove consistencyCulture processSkeletal/connective tissue cellsHeterologousCell cycle
The invention relates to a serum-free culture medium for mesenchymal stem cells and application thereof. The serum-free culture medium comprises a basal culture medium and additive components. The additive components comprise the following components: 2'-Deoxyadenosine, 2'-Deoxycytidine-HCl, 2'-Deoxyguanosine, L-glutamine, human serum albumin, recombinant human transferrin, recombinant human insulin, rhPDGF-BB, rhFGF-b, rhTGF-beta1, rhEGF, sodium selenate and hydrocortisone. The serum-free culture medium disclosed by the invention does not contain animal-derived heterologous component such asbovine serum, and can effectively replace serum to culture bone marrow mesenchymal stem cells; and due to the synergistic effect of the additive components, the culture medium has the advantages of shortening cell cycle, rapid proliferation and good cell consistency while culturing bone marrow mesenchymal stem cells, and can effectively maintain the molecular characteristics and differentiation potential of the bone marrow mesenchymal stem cells. The bone marrow mesenchymal stem cells obtained by the culture medium are suitable for further scientific research and clinical application research.
Owner:苏州依科赛生物科技股份有限公司
Method and kit for determining metabolites on dried blood spot samples
ActiveUS20120273671A1Easy to implementAvoid serious complicationsIsotope separationMass spectrometersMetaboliteDay of life
A method for individuating with high sensitivity and specificity ADA metabolites from dried blood spot. The method described herein can be used to extract Adenosine and Deoxyadenosine from a sample under conditions that permit concurrently extracting other metabolites, such as amino acids, free carnitine, or acylcarnitines. For example, harsh extraction conditions (such as extreme acidity and high temperature) can be avoided. The method can be used, along with other neonatal screenings, on blood samples and preferably on dried blood spots (Guthrie cards) and more preferably on Guthrie cards obtained in the II-IV day of life. The method is reliable and reproducible, easy to perform and gives a definitive response within a short time (1-2 days). One or more kit for use in the method.
Owner:AZIENDA OSPEDALIERO UNIVRIA MEYER
Process for preparing dideoxyinosine using adenosine deaminase enzyme
InactiveUS20040175804A1Improve enzyme stabilityEasy to separateBiocideSugar derivativesDeaminase activityDideoxyadenosine
A method of making didanosine (ddI) including the steps of: (a) obtaining an enzyme expressing ddA deaminase activity; (b) immobilizing the enzyme onto an insoluble support; (c) contacting the enzyme with a dideoxyadenosine (ddA) solution of at least about 4% weight volume ddA in water for a time and under conditions to produce a ddI solution; and (d) isolating the ddI from the ddI solution. Optionally, the ddI mother liquor is reused in subsequent runs to improve yield.
Owner:BRISTOL MYERS SQUIBB CO
Activity-based assay for ricin-like toxins
InactiveUS20060057596A1Sensitive highEasy to adaptSugar derivativesMicrobiological testing/measurementPositive controlRicin
A method of detecting N-glycosylase activity in a sample involves incubating an oligodeoxyribonucleotide substrate containing a deoxyadenosine or deoxyuridine residue with the sample to be tested such that the N-glycosylase, if present, hydrolyzes the deoxyadenosine or deoxyuridine residue to result in an N-glycosylase product having an abasic site. A primer is annealed to the N-glycosylase product, and the primer is extended with a DNA polymerase, such as Taq DNA polymerase, that pauses at abasic sites. The resulting extension products are melted from the N-glycosylase product, allowed to form hairpins due to self-complementarity, and further extended in the presence of labeled precursors to result in labeled products. Extension products synthesized from undigested substrate as template do not result in labeled products. Thus, detection of labeled products results in detection of N-glycosylase activity. Oligodeoxyribonucleotide substrates, primer, and positive controls and a kit for N-glycosylase assay are also disclosed.
Owner:BATTELLE ENERGY ALLIANCE LLC
Method for producing deoxyadenosine by bioconversion method
InactiveCN101575630ATake advantage of specificityTake advantage of gentlenessMicroorganism based processesFermentationChemical synthesisDrug biotransformation
The invention discloses a method for producing deoxyadenosine by a bioconversion method, comprising the following steps of: inoculating swiss lactobacillus seed liquid in a fermentation medium for fermentation and culture, thus obtaining a crude strain; crushing the crude strain to prepare a cell homogenates; and adding a deoxythymidine and a adenine in the cell homogenates for enzymatic reaction, thus obtaining the deoxyadenosine; the fermentation medium comprises the following substances by weight portion: 10-20 portions of dextrose, 1-5 portions of peptone, 10-25 portions of corn gluten, 1-2 portions of citric acid amino, 1-2 portions of potassium phosphate dibasic, 5-10 portions of sodium sulfate, 0.02-0.4 portions of manganese sulfate and 1000 portions of water; and the granularity of the adenine is less than or equal to 10 microns. The method for producing the deoxyadenosine by the bioconversion method sufficiently utilizes the high effectiveness, specificity and moderateness of the enzyme, and has the advantages of high selectivity, moderate condition, simple process, low cost, small pollution and the like compared with the traditional chemical synthesis method.
Owner:SHANDONG JIANWEI BIOENG
Use of cladribine for treating autoimmune inflammatory disease
2-Chloro-2′-deoxyadenosine, hereinafter referred to as cladribine, or a pharmaceutically acceptable salt thereof may be used in the treatment or amelioration of neuromyelitis optica, hereinafter referred to as NMO e.g. in patients known to have NMO-IgG seropositivity or in patients optic neuritis, myelitis and at least two of MRI evidence of contiguous spinal cord lesion 3 or more segments in length, onset brain MRI nondiagnostic for multiple sclerosis or NMO-IgG seropositivity.
Owner:CHORD THERAPEUTICS S A R L
Method for converting escherichia coli to produce 2'-deoxyadenosine
ActiveCN104178541AEasy to separate and purifyImprove conversion rateSugar derivativesMicroorganism based processesEscherichia coliFeed conversion ratio
The invention discloses a method for converting escherichia coli to produce 2'-deoxyadenosine. Escherichia coli thallus with high nucleoside phosphorylase activity is directly adopted as an enzyme source to mix with deoxythymidine which is taken as a conversion reaction substrate as well as adenine to carry out conversion reaction to synthesize 2'-deoxyadenosine. The method has the advantages of simple process, high conversion ratio, low production cost and gentle reaction conditions; moreover, the by-products are fewer, green and pollution-free, and the products are easy to separate and purify. A conversion ratio of adenine is over 72.5%. Besides, the 2'-deoxyadenosine is separated and purified by adopting a method of crystallization and recrystallization, so that the purity of the 2'-deoxyadenosine is over 99%.
Owner:西藏天虹科技股份有限责任公司
Method for purification of natural cobalamins by adsorption on insoluble materials containing carboxylic groups
InactiveCN102131820APurification procedure worksImprove bindingOrganic active ingredientsCation exchanger materialsElutionCobalamin
The present invention relates to a method for purification and / or concentration of natural cobalamins by adsorption on insoluble materials containing carboxylic groups. Especially the method comprises providing a first solution comprising at least one type of natural cobalamins, providing an adsorbent material comprising carboxylic groups capable of making specific interaction with said natural cobalamins, contacting said first solution comprising at least one type of natural cobalamins with said adsorbent material, whereby at least a part of said at least one type of natural cobalamins becomes adsorbed and / or bound to said adsorbent material, and elution of said at least one type of natural cobalamins from said adsorbent material, hereby obtaining a concentrated solution comprising at least one cobalamin. The natural cobalamins can be one or more of the natural cobalamins 5'-deoxy-5'-adenosyl-Cobalamin (adenosyl- Cbl, Ado Cbl), methyl-cobalamin (methyl-Cbl, Me Cbl) and aquo-cobalamin (aquo-Cbl, H2O Cbl).
Owner:谢尔盖・尼科拉耶维奇・费多索夫
Synthetic method for cordycepin
ActiveCN104961787AMild reaction conditionsLow equipment requirementsSugar derivativesSugar derivatives preparationKetoneEthyl acetate
The invention discloses a synthetic method for cordycepin. The method comprises the following steps: with adenosine as a starting material, subjecting adenosine and Mattock's bromide to bromination in a reaction solvent of acetonitrile and / or ethyl acetate during implementation of hydroxyl protection so as to obtain two products, i.e., 5'-[2,5,5-trimethyl-1,3-dioxolane-4-one-2-yl]-3'-bromo-3'-deoxy-2'-O-acetyl adenosine and 5'-[2,5,5-trimethyl-1,3-dioxolane-4-one-2-yl]-2'-bromo-2'-deoxy-3'-O-acetyl adenosine; then removing protective groups so as to obtain 3'-bromo-3'-deoxy-adenosine hydrochloride; and subjecting 3'-bromo-3'-deoxy-adenosine hydrochloride to debromination so as to obtain 3'-deoxyadenosine, i.e., cordycepin. The synthetic method provided by the invention is simple to operate, has short reaction steps and does not need purification in the process of reaction; and the purity and each index of the obtained cordycepin product are better than a currently commercially available cordycepin product.
Owner:SHENZHEN SUNNY BIO TECH CO LTD
Chemical synthesis method for producing 2'-dexoyadenosine
InactiveCN101007830AHigh catalytic efficiencyStrong specificitySugar derivativesChemical synthesisPhenacyl
The invention discloses a chemical process of preparing 2'- desoxyadenosine, relating to a process for synthesizing organic compound. The process comprises following steps: (1) putting 6- chloride adenine and 1- acetyl base- 3, 5- bi (4-methyl phenacyl)- 2- deoxyribose and organic solvent containing phosphate phenolic ester compound catalyst into autoclave; carrying out condensation reaction under catalytic action to prepare 3', 5'- bi (4-methyl phenacyl)- 2'- deoxy- 6- chloride purine nucleosides; (2) putting compound and ammonia methanol into autoclave for aminolysis, the consumption amount of ammonia methanol is 4- 8 times of that of compound, the temperature is 10- 50 Deg. C, getting 2'- desoxyadenosine after aminolysis.
Owner:HENAN NORMAL UNIV +1
A kind of synthetic method of 2'-deoxyadenosine
InactiveCN105884846BHigh selectivityHigh yieldSugar derivativesSugar derivatives preparationChromatographic separationSynthesis methods
Owner:CENT SOUTH UNIV
Activity-based assay for ricin-like toxins
InactiveUS7172861B2Sensitive highEasy to adaptSugar derivativesMicrobiological testing/measurementPositive controlRicin
Owner:BATTELLE ENERGY ALLIANCE LLC
Application of 3'-deoxyadenosine in reducing weight, enhancing insulin sensitivity and improving lipid metabolism
ActiveCN101574144ADecreased glucose toleranceReduced activityOrganic active ingredientsMetabolism disorderSecondary hyperlipidemiaCholesterol blood
The invention discloses application of 3'-deoxyadenosine in reducing weight, enhancing insulin sensitivity and improving lipid metabolism, and particularly relates to the application of the 3'-deoxyadenosine shown in a formula (1), which is used as a weight reduction pill, an insulin sensitizer and a blood fat regulator, in medicaments and / or health care products, in particular to the application of the 3'-deoxyadenosine in preventing and treating hypercholesterolemia, mixed type hyperlipidemia, and dyslipoproteinemia.
Owner:INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Complex containing oligonucleotide having immunopotentiating activity and use thereof
ActiveUS10202606B2High activityImprove protectionAntibacterial agentsSsRNA viruses negative-senseCpG OligodeoxynucleotideDeoxyadenosine
Owner:NAT INST OF BIOMEDICAL INNOVATION HEALTH & NUTRITION +1
Alkynyl modified deoxyadenosine phosphoramidite monomer and preparation method thereof
ActiveCN109970832AHigh yieldRaw materials are easy to getSugar derivativesSugar derivatives preparationTwo stepOrganic chemistry
The invention belongs to the technical field of medicines, and discloses a synthetic method and an application of an alkynyl modified deoxyadenosine phosphoramidite monomer compound. According to themethod, an N6 position of deoxyadenosine is carboxylated and modified by alkynyl to obtain an intermediate, and protection of a 5'-terminal hydroxyl group and two-step reaction of 2'-phosphoramidite are implemented to obtain the alkynyl modified deoxyadenosine phosphoramidite monomer compound. Solid-phase synthesis of DNA (deoxyribonucleic acid) is implemented, and the DNA is leaded into oligonucleotide in a fixed point manner to obtain artificial genomic loci alkynyl modified oligonucleotide. The alkynyl modified deoxyadenosine phosphoramidite monomer compound is applied to oligonucleotide alkynyl modification, the method is simple, yield is considerable, new ideas and high-value intermediates are provided for follow-up DNA functionalization, and the compound is wide in application prospects.
Owner:SHENYANG PHARMA UNIVERSITY
Biosynthesis gene cluster of 2'-chloropentostatin and 2'-amino-2'-deoxyadenosine and application thereof
ActiveCN106676115AUnderstanding Biosynthetic MechanismsImprove dynamic characteristicsHydrolasesMicroorganism based processesActinomadura maduraeBiosynthetic genes
The invention relates to cloning, sequencing, analysis and functional research of a biosynthesis gene cluster of 2'-chloropentostatin and 2'-amino-2'-deoxyadenosine and application thereof. The 2'-chloropentostatin is a natural product produced by actinomadura madurae ATCC 39365 and is used for treating leukemia; the 2'-amino-2'-deoxyadenosine is a natural product of RNA (ribonucleic acid) viruses of anti-mycoplasma virus, measles virus and the like. The whole gene cluster contains 13 genes, wherein five genes are related with synthesis of the 2'-chloropentostatin; four genes are related with synthesis of the 2-amino-2'-deoxyadenosine; four genes are related with transfer and regulation of the 2'-chloropentostatin and the 2-amino-2'-deoxyadenosine. The biosynthesis of the 2'-chloropentostatin and the 2-amino-2'-deoxyadenosine is blocked or improved by the genetic manipulation on the biosynthesis gene. The gene and the protein thereof can be applied to the gene engineering, protein expression, enzyme catalytic reaction and the like of the compound, and be used for looking and finding compounds, genes and proteins for medicines, industry or agriculture.
Owner:WUHAN UNIV
Complex containing oligonucleotide having immunopotentiating activity and use thereof
ActiveUS20160208260A1Superior immunostimulating activityStrong adjuvant activityAntibacterial agentsSsRNA viruses negative-senseNucleotideCpG Oligodeoxynucleotide
The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3′-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and β-1,3-glucan.
Owner:NAT INST OF BIOMEDICAL INNOVATION HEALTH & NUTRITION +1
Self-assembled nano material as well as preparation method and application thereof
ActiveCN111686815ALow priceEasy to scale applicationMaterial nanotechnologyOrganic-compounds/hydrides/coordination-complexes catalystsFluorescenceThymidine monophosphate
The invention discloses a self-assembled nano material. formed by nucleic acid or nucleotide, an amino acid derivative or polypeptide and copper ions through self-assembly. The type of the amino acidderivative is lysine, histidine, methionine or cysteine; the chiral configuration is L-shaped or D-shaped; the polypeptide contains histidine, methionine, lysine or cysteine; the length of the peptideis 2 peptide-40 peptide; the nucleic acid is DNA; the molar ratio of guanine deoxynucleotide in DNA is 10%-100%, the total number of the nucleotides is 4-59, and the nucleotide is guanosine-5'-monophosphate, adenosine-5'-monophosphate, cytidine-5'-monophosphate, uridine-5'-monophosphate, deoxyguanosine-5'-monophosphate, deoxyadenosine-5'-monophosphate, deoxycytidine-5'-monophosphate or thymidine-5'-monophosphate. According to the invention, the simulated enzyme catalytic reaction can be monitored through a light absorption or fluorescence photometer.
Owner:BEIJING UNIV OF CHEM TECH
Applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis
InactiveCN103893200AImprove antioxidant capacityScavenging active oxygenOrganic active ingredientsMetabolism disorderDiseaseCholesterol
The invention relates to medical novel applications of cordycepin (3'-deoxyadenosine), and more specifically relates to applications of cordycepin used for preparation of medicines used for preventing and treating atherosclerosis and atherosclerosis related diseases. It is confirmed by pharmacodynamic experiments that: cordycepin is capable of inhibiting formation of ApoE- / - mice aorta atherosclerotic plaques significantly, reducing serum TC, TG, and LDL-c contents of animals with hyperlipidemia, increasing total antioxidant capacity and SOD activity of animal serum, reducing MDA content, reducing contents of serum interleukin 2 and interleukin 8 significantly, and inhibiting inflammation. It is confirmed by cell experiments that: cordycepin is capable of inhibiting uptake of mononuclear cell RAW267.4 on cholesterol significantly, and promoting flowing of cholesterol out from cells.
Owner:INST OF MEDICINAL PLANT DEV CHINESE ACADEMY OF MEDICAL SCI
Ruthenium mixed-polypyridyl complex, preparation thereof and use as antitumor drug
InactiveCN101348504AInhibition of replicationReduce the binding forceOrganic active ingredientsGroup 8/9/10/18 element organic compoundsLithium chlorideCoordination complex
Owner:GUANGDONG PHARMA UNIV
Method for the production of cladribine
InactiveUS20100291632A1Improve isolationHigh yieldOrganic chemistryFermentationPurine nucleoside phosphorylaseSolvent
A method for producing cladribine (2-chloro-2′-deoxyadenosine) comprising the steps of:a) reaction of 2-deoxyuridine with 2-chloroadenine, in the presence of uridine phosphorylase (UPase) and purine nucleoside phosphorylase (PNPase) in an aqueous reaction medium possibly containing up to 40% v / v of an aprotic dipolar solvent, to obtain cladribine dissolved in said reaction medium;b) isolation of the cladribine by precipitation by means of concentration and alkalinisation of the reaction medium up to pH 11.5-12.5.
Owner:EXPLORA LAB
Method for determining nucleotide metabolites in filter paper dried blood spots
The invention provides a method for determining nucleotide metabolites in a filter paper dried blood spot. The nucleotide metabolites comprise adenosine, 2'-deoxyadenosine, guanosine, 2'-deoxyguanosine, inosine and 2'-deoxyinosine. The method comprises the following steps: 1) performing extraction treatment on a to-be-detected filter paper dried blood slice in an extraction working solution to obtain an extraction solution containing the nucleotide metabolite; 2) carrying out liquid chromatography-mass spectrometry detection on the extract liquor; and 3) determining the yield of the nucleotidemetabolites in the filter paper dried blood spot based on a liquid chromatography separation-mass spectrometry detection result. According to the detection method provided by the embodiment of the invention, six nucleotide metabolites in the filter paper dried blood spot can be simultaneously detected, and the detection method is used for scientific research or synchronous screening and diagnosisof ADA and PNP diseases, so that the detection cost is reduced, and the efficiency is improved. The method has the advantages of high sensitivity, strong specificity and high accuracy.
Owner:SHENZHEN HUADA GENE INST
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com